Join the Glaucoma (Open Angle) group to help and get support from people like you.
Glaucoma (Open Angle) News
AI Outperforms Glaucoma, Retina Specialists for Diagnostic Accuracy
WEDNESDAY, Feb. 28, 2024 – A large language model (LLM) chatbot outperforms glaucoma and retina specialists for diagnostic accuracy, according to a study published online Feb. 22 in JAMA...
AI Outperforms Eye Docs in Managing Glaucoma
FRIDAY, Feb. 23, 2024 (HealthDay news) – Artificial intelligence can match and even outperform human eye doctors in diagnosing and treating glaucoma, a new study finds. The GPT-4 system from OpenAI...
Home Lighting Tied to Activity Levels in Adults With Visual Impairment
FRIDAY, Feb. 9, 2024 – The home environment, particularly lighting, may influence home activity metrics in older adults with visual impairment, according to a study published online Feb. 8 in JAMA ...
Black People Far More Likely to Get Glaucoma, and Genes May Explain Why
TUESDAY, Jan. 23, 2024 – Black people are five times as likely as others to develop glaucoma and up to 15 times more likely to be blinded by the degenerative eye disease. Now, a new study reports...
Know the Facts About Glaucoma
TUESDAY, Jan. 2, 2024 – Glaucoma can steal your sight before you even realize it, and early diagnosis is the best way to prevent it. Many of the 3 million Americans who have glaucoma are unaware of...
FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma
ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment...
Deep-Learning Models Can Predict Conversion to Normal-Tension Glaucoma
FRIDAY, Nov. 3, 2023 – Deep learning models trained with fundus images and clinical data can predict whether normotensive glaucoma suspect (GS) eyes will convert to normal-tension glaucoma (NTG),...
Half of Older Adults With Glaucoma Unaware They Have It
TUESDAY, Sept. 12, 2023 – Many older adults with glaucoma may be undiagnosed, according to a study published online July 17 in Acta Ophthalmologica. Lena Havstam Johansson, from the University of...
Adverse Association Identified for Calcium Channel Blocker Use, Glaucoma
FRIDAY, Sept. 8, 2023 – There is an adverse association between calcium channel blocker (CCB) use and glaucoma, according to a study published online Sept. 7 in JAMA Ophthalmology. Alan Kastner,...
Some With Glaucoma May Not Even Know They Have It
FRIDAY, Sept. 8, 2023 – New Swedish research suggests that up to 5% of 70-year-olds have glaucoma, and half of those diagnosed didn't even know they had the disease. “Of those who were diagnosed w...
Glaucoma: Spotting It Early Is Crucial
FRIDAY, July 14, 2023 – Treatment can control the symptoms of the most common type of glaucoma and save someone’s vision. The catch is that a person can’t feel the changes in eye pressure that can da...
FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Iyuzeh™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LE...
FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE) September 26, 2022 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the...
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
DUBLIN, March 5, 2020 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug...
FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.C.--(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and...
Ask a question
To post your own question to this support group, sign in or create an account.